This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer

This study has been terminated.
Astellas Pharma US, Inc.
Information provided by:
Astellas Pharma Inc Identifier:
First received: December 3, 2002
Last updated: June 6, 2012
Last verified: June 2012
The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.

Condition Intervention Phase
Prostate Cancer Drug: YM598 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Study Completion Date: February 2004

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00050297

University Clinic AZ
Brussels, Belgium
University Clinic UCL St. Luc
Brussels, Belgium
Czech Republic
Private Urology Out-patient Ward
Jablonec nad Nisou, Czech Republic
Clinic of Urology, University Hospital
Králové, Czech Republic
Clinic of Urology, University Hospital
Olomouc, Czech Republic
Clinic of Urology, University Hospital
Prague, Czech Republic
Hôpital Bichat, service de Urology
Paris, France
Haingasse 22
Bad Homburg, Germany, 61348
Klinik und Poliklinik für Urologie, Universitätsklinikum Carl-Gustav-Carus
Dresden, Germany
Klinik u. Poliklinik für Urologie, Philipps Universität, Baldingerstraße
Marburg, Germany
Krummbogen 15
Marburg, Germany
Regional Hospital, Department of Urology
Bydgoszcz, Poland
MedSource Poland
Gdansk, Poland
Bielanski Hospital, Department of Urology
Warszawa, Poland
Oncology Center, Department of Urinary Tract Cancer
Warszawa, Poland
Medical University, Clinic of Urology
Wroclaw, Poland
Complejo Hospitaliaro Juan Canalejo, Servicio de Urología
Corunna, Spain
Fundacion Hospital Alcorcón, Servicio Urología
Madrid, Spain
Hospital Universitario Principe de Asturias, Servicio de Urología, Ctra.
Madrid, Spain
United Kingdom
Department of Urology, Bristol Royal Infirmary
Bristol, United Kingdom
Department of Urology, Gartnavel Hospital
Glasgow, United Kingdom
Department of Urology, Norfolk & Norwich Hospital
Norwich, United Kingdom
Department of Urology, Taunton & Somerset Hospital
Taunton, United Kingdom
Sponsors and Collaborators
Astellas Pharma Inc
Astellas Pharma US, Inc.
  More Information Identifier: NCT00050297     History of Changes
Other Study ID Numbers: 598-CL-004
Study First Received: December 3, 2002
Last Updated: June 6, 2012

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Endothelin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017